# Retatrutide in Type 2 Diabetes: Why TRANSCEND-T2D-1 Reads Lower Than Phase 2 TRANSCEND-T2D-1 randomized 537 adults with type 2 diabetes to retatrutide or placebo. HbA1c fell up to 1.94 points against 0.81 on placebo, and weight 15.3% against 2.6%. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/retatrutide-transcend-t2d-1 Updated: 2026-09-17 Published: 2026-09-17 [← Research](https://thisglp.com/research) Evidence # Retatrutide in Type 2 Diabetes: Why TRANSCEND-T2D-1 Reads Lower Than Phase 2 Weight fell 15.3% at the top dose here, against 24.2% in the phase 2 obesity trial. Different populations over different durations — not a weaker drug. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min read Weight change at 12 mg, two different populations · obesity, no diabetes · −24.2% · type 2 diabetes · −15.3% · 48 weeks against 40. Not the same comparison. · Weight loss runs smaller in diabetes across this whole class. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Retatrutide targets three receptors — GIP, GLP-1 and glucagon. TRANSCEND-T2D-1 is its first phase 3 readout in type 2 diabetes. - In 537 adults over 40 weeks, HbA1c fell 1.69, 1.86 and 1.94 points at 4, 9 and 12 mg, against 0.81 on placebo. - The treatment differences are about half those figures: -0.88, -1.04 and -1.12 points, all at p<0.0001. - Weight fell 15.3% at 12 mg here, against 24.2% in the phase 2 obesity trial — different populations, not a weaker drug. Retatrutide has been the most-hyped molecule in the pipeline for two years. That rests on a phase 2 obesity trial which took off nearly a quarter of body weight. Its first phase 3 result in type 2 diabetes reports 15.3%, and the gap between those two numbers is the thing most likely to be misread. This site covered the molecule’s [first-in-human data](https://thisglp.com/research/triple-agonist-first-in-human) when it appeared. ## What TRANSCEND-T2D-1 measured The trial randomized 537 adults whose type 2 diabetes was inadequately controlled by diet and exercise alone, at 48 sites across the USA, Mexico and India [\[1\]](https://thisglp.com/research/retatrutide-transcend-t2d-1#ref-1). Average age was 48.8, average HbA1c 7.9%, average BMI 35.8, and average diabetes duration 2.5 years. These were people early in the disease, which is the easiest setting for a glucose drug. HbA1c fell 1.69 points at 4 mg, 1.86 at 9 mg and 1.94 at 12 mg. The placebo arm fell 0.81 points over the same 40 weeks. That is large for a placebo, and it changes what the drug can be said to have done on its own. The arm change and the treatment difference are different numbers Against placebo the estimated treatment differences were 0.88, 1.04 and 1.12 points, roughly half the raw arm change at every dose. A page quoting “nearly two points of HbA1c” is quoting the arm rather than the drug’s effect. This site set out the same slippage in [a trial result extrapolated to everyone](https://thisglp.com/research/how-many-heart-attacks-could-semaglutide-prevent). ## Why the weight number looks smaller than you remember The two headline figures come from different trials in different people. | | Phase 2 | TRANSCEND-T2D-1 | | --- | --- | --- | | Population | Obesity, no diabetes | Type 2 diabetes | | Participants | 338 | 537 | | Duration | 48 weeks | 40 weeks | | Weight at 12 mg | −24.2% | −15.3% | | Placebo arm | −2.1% | −2.6% | The two headline figures come from different trials in different people. Phase 2 obesity trial and TRANSCEND-T2D-1 The phase 2 trial enrolled adults with obesity and without diabetes. It reported 8.7%, 17.1%, 22.8% and 24.2% across 1, 4, 8 and 12 mg at 48 weeks, against 2.1% on placebo [\[2\]](https://thisglp.com/research/retatrutide-transcend-t2d-1#ref-2). At 12 mg, 83% of participants lost at least 15% of their body weight, against 2% on placebo. Setting 24.2% beside 15.3% therefore compares two different populations over two different durations. Weight loss runs consistently smaller in people with type 2 diabetes across this entire drug class, which is the established explanation rather than a sign that this drug underperformed. The molecule-by-molecule version of that pattern is in [the pooled weight-loss averages](https://thisglp.com/research/glp1-weight-loss-pooled-average). ## Safety, as reported Discontinuation for adverse events ran 2% to 5% on retatrutide and 0% on placebo, with gastrointestinal events most common and generally mild to moderate. No severe hypoglycemia was reported. Two deaths occurred during the study, both in the 4 mg group, and the paper describes both as unrelated to the study drug. That is what the record says. It is not evidence of a dose-related hazard, since the two higher doses had none, and two events in a 537-person trial cannot establish a rate either way. The phase 2 trial also recorded dose-dependent increases in heart rate that peaked at 24 weeks and declined afterwards. It found gastrointestinal events were partly mitigated by starting at 2 mg rather than 4 mg. That is the same escalation logic set out in [what titration does to the nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1). ## What this does not settle Retatrutide is not approved and is not sold, a point worth repeating because the name circulates in gray-market listings — covered in [what is not for sale](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming). This trial also used placebo rather than an active comparator, so it establishes that a third receptor does not obviously break anything at 40 weeks in an easy population. Whether it beats the drugs already on pharmacy shelves is a different question, and nobody has run it. ## Frequently asked How much weight did retatrutide take off in type 2 diabetes? 15.3% at 12 mg over 40 weeks, against 2.6% on placebo, in 537 adults whose diabetes was inadequately controlled by diet and exercise. Why is that lower than the 24% everyone quotes? The 24.2% came from a phase 2 trial in adults with obesity and without diabetes, over 48 weeks. Weight loss runs consistently smaller in people with type 2 diabetes across this whole drug class. How much did it lower HbA1c? Arm changes were 1.69, 1.86 and 1.94 points at 4, 9 and 12 mg. Because placebo fell 0.81 points, the treatment differences were 0.88, 1.04 and 1.12 points. Were there deaths in the trial? Two, both in the 4 mg group, which the paper reports as unrelated to the study drug. The two higher doses had none. Can I buy retatrutide? No. It is investigational, not approved anywhere, and not sold by any seller this site tracks. ## Sources 1. \[1\] Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B (2026). Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial The Lancet. [PMID 42250575](https://pubmed.ncbi.nlm.nih.gov/42250575/) 2. \[2\] Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial The New England Journal of Medicine. [PMID 37366315](https://pubmed.ncbi.nlm.nih.gov/37366315/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)